NCT03979521 (Mya-BoD) is a clinical trial in Myasthenia Gravis, sponsored by Charite University, Berlin, Germany.

Who is sponsoring NCT03979521?

NCT03979521 is sponsored by Charite University, Berlin, Germany.

What condition does NCT03979521 study?

NCT03979521 studies Myasthenia Gravis.

Is NCT03979521 still recruiting?

NCT03979521 is currently completed. Last updated 4 January 2022.

Last reviewed 2022-01-04 · How we verify

NCT03979521: Mya-BoD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Burden of Disease in Myasthenia Gravis

Completed Last updated 4 January 2022

What this trial tests

trial in Myasthenia Gravis in 1,680 participants. Completed in 31 July 2019.

Timeline

1 May 2019

Primary endpoint
31 July 2019

31 July 2019

Quick facts

Lead sponsor	Charite University, Berlin, Germany
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,680
Start date	1 May 2019
Primary completion	31 July 2019
Estimated completion	31 July 2019
Sites	1 location across Germany

Conditions studied

Myasthenia Gravis — all drugs for Myasthenia Gravis →

Sponsor

Charite University, Berlin, Germany

Who can join

18 and older, any sex, with Myasthenia Gravis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Questionnaire-based survey addressed to german patients with the chronic autoimmune muscle disease called myasthenia gravis regarding quality of life, socioeconomic impact, social support, course of disease, complications of therapy and psychological comorbidities.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Burden of disease in myasthenia gravis: taking the patient's perspective.
Lehnerer S, Jacobi J, Schilling R, Grittner U, et al · · 2022 · cited 114× · PMID 34800167 · DOI 10.1007/s00415-021-10891-1
The burden of disease in seronegative myasthenia gravis: a patient-centered perspective.
Lehnerer S, Stegherr R, Grittner U, Stein M, et al · · 2025 · cited 5× · PMID 40264778 · DOI 10.3389/fimmu.2025.1555075
The economic burden of Myasthenia gravis from the patient´s perspective and reflected in German claims data.
Lehnerer S, Herdick M, Mevius A, Grittner U, et al · · 2025 · cited 3× · PMID 39994434 · DOI 10.1038/s41598-025-91372-7
The burden of myasthenia gravis - highlighting the impact on family planning and the role of social support.
Stein M, Grittner U, Stegherr R, Gerischer L, et al · · 2023 · cited 3× · PMID 38162439 · DOI 10.3389/fneur.2023.1307627

Verify or expand the search:

Other recruiting trials for Myasthenia Gravis

Currently open trials in the same condition.

NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07217587 — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis · Phase 3 · recruiting
NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
NCT07246564 — Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni · Phase 4 · recruiting

Other Charite University, Berlin, Germany trials

Trials by the same sponsor.

NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03979521 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
Last refreshed: 4 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03979521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing